Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 27, No 15S (May 20 Supplement), 2009: LBA5509
© 2009 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Pujade-Lauraine, E. Articles by Ferrero, A. Search for Related Content PubMed Articles by Pujade-Lauraine, E. Articles by Ferrero, A.

Abstract

A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG)

GINECO, Paris, France; AGO-OVAR, Hamburg, Germany; NSGO, Oslo, Norway; ANZGOG, Sydney, Australia; NCIC-CTG, Vancouver, BC, Canada; ANZGOG, Queensland, Australia; AGO-Austria, Vienna, Austria; EORTC, Leuven, Belgium; MITO, Napoli, Italy; MANGO, Torino, Italy

LBA5509

The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology.

No significant financial relationships to disclose.

Abstract presentation from the 2009 ASCO Annual Meeting